Metformin treatment in NIDDM patients with mild renal impairment

Postgraduate Medical Journal

Volumn 72, Issue 848, 1996, Pages 352-354

  Connolly, Vincent ^a,b   Kesson, Colin M ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Lactate; Metformin

Indexed keywords

CREATININE; CYANOCOBALAMIN; LACTIC ACID; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG CONTRAINDICATION; FEMALE; HUMAN; KIDNEY FAILURE; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0029946976     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.72.848.352     Document Type: Article

References (26)

1. Williams RH, Palmer JP. Farewell to phenformin for treating diabetes mellitus. Ann Intern Med 1975; 83: 567-68.
2. Nattrass M, Alberti KGMM. Biguanides. Diabetologia 1978; 14: 71-4.
3. Bailey CJ. The anti-hyperglycaemic action of metformin. R Soc Med Int Congr Symp Ser 1985; 79: 17-26.
4. Bailey CJ. Metformin revisited: its actions and indications for use. Diabetic Med 1988; 5: 315-20.
5. UK Prospective Study of Therapies of Maturity-onset Diabetes: 1 Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Multi-centre study. Diabetologia 1983; 24: 40-11.
6. Sterne J, Junien JL. Metformin: pharmacological mechanisms of the anti-diabetic and antilipidec effects and clinical consequences. R Soc Med Int Congr Symp Ser 1981; 48: 3-16.
7. Hermann LS. Metformin a review of its pharmacological properties and therapeutic use. Diabetes Metab Rev 1979; 5: 233-45.
8. UK Prospective Diabetes Study 11. Reduction in HbA1c with basal insulin supplement, sulphonylurea or biguanide therapy in maturity onset diabetes. Diabetes 1985; 24: 793-8.
9. Wales JK. Treatment of the obese diabetic patient. In: Bjorntorp P, Cairelli M, Howard AN, eds. Recent advances in obesity research. London: Libby, 1980; pp 184-9.
10. Wu MS, Johnston P, Sheu WHH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8.
11. Chakrabarti R, Hocking ED, Fearnley GR. Fibrinolytic effect of metformin in coronary artery disease. Lancet 1965; 2: 256-9.
12. DeSilva SR, Shawe JE, Patel H, Cudworth AG. Plasma fibrinogen in diabetes mellitus. Diabete Metab 1979; 5: 201-6.
13. Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ. Metabolic and haemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993; 16: 1035-8.
14. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57: 326-8.
15. Robertson DA, Hale PJ, Nattrass M. Macrovascular disease and hyperinsulinaemia. Clin Endocrinol Metab 1988; 2: 407-24.
16. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-70.
17. Noll F. Methods of enzymatic analysis. 2nd edn. HU Bergmeyer, p1475.
18. Prager R, Schernthaser G, Graf H. Effect of metformin on peripheral insulin sensitivity in non-insulin dependent diabetes mellitus. Diabete Metab 1986; 12: 346-50.
19. Gawler DJ, Milligan G, Houslay MD. Treatment of streptozocin rats with metformin restores the ability of insulin to inhibit adenylate cyclase activity. Biochem J 1988; 249: 537-42.
20. Nattrass M, Todd PG, Hinks L, Lloyd B, Alberti KGMM. Comparative effects of phenformin, metformin, and glibenclamide on metabolic rhythms in maturity onset diabetes. Diabetologia 1977; 13: 145-52.
21. Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums 1979; 1: 35-50.
22. Pentikainen PJ, Neuivonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195-202.
23. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-46.
24. Wiholm BE, Myrhed M. Metformin associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993; 44: 589-91.
25. Langan SJ, Deary IJ, Hepburn DA, Frier BM. Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus. Diabaologia 1991; 34: 337-44.
26. Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. BMJ 1988; 296: 949-50.